Ironwood

Analysts at JPMorgan no longer hold a bullish view on Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) after the company released top-line results from a phase 2b trial called IW-3718. The firm's Anupam Rama downgraded Ironwood's stock from Overweight to Neutral with a price target lowered...